Shionogi
OTC:SGIOFPharmaOsaka, Japan, Japan · Est. 1878 · 12,000 employees
Shionogi is a Japanese pharmaceutical company focused on developing and commercializing innovative medicines in infectious diseases, oncology, and other therapeutic areas.
4
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
4
Indications↗
Distinct diseases across all programs
108
Clinical Trials↗
All sponsored trials (all statuses)
18
Orange Book Patents
Across 3 drugs with upcoming expirations
Pipeline
Pipeline Snapshot
By Phase
4 drugs in development
Phase 23
Phase 11
By Therapeutic Area
top 2
Infectious Disease
125%
Oncology
125%
R&D Momentum
52/100
Pipeline Velocity
27/100
Trial Completion Rate
91/100
Pipeline Concentration
38/100
Pipeline Freshness
88/100
Strategic Signals
- ↗Early-stage heavy pipeline may seek late-stage partners
- ↗Active in Infectious Disease but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Last 14 days
Sep 18, 2026
Recruiting
A Phase 3 Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Secutrelvir in Participants With COVID-19 Who Are at High Risk for Progression to Severe Disease
Sep 17, 2026
Completed
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of S-217622 in the Prevention of Symptomatic SARS-CoV-2 Infection in Household Contacts of an Individual With Symptomatic COVID-19
Earlier
Sep 3, 2026TrialA Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Secutrelvir in Participants With COVID-19
Sep 2, 2026TrialA Phase 1, Multicenter, Nonrandomized, Open-label, Parallel-group Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of S-892216-PO in Participants With Varying Degrees of Renal Impairment and Matched Control Participants With Normal Renal Function
Aug 27, 2026TrialA Phase 1b, Multicenter, Single-arm, Open-label Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of S-606001 as a Monotherapy in Adult Patients With Late-onset Pompe Disease
Aug 21, 2026TrialA Phase 3b, Multicenter, Randomized, Double-blind Extension Study to Evaluate the Continued Efficacy and Safety of Oral Edaravone Administered for an Additional Period of up to 48 Weeks Following Study MT-1186-A02 in Subjects With Amyotrophic Lateral Sclerosis (ALS)
Aug 21, 2026TrialA Phase 3, Multicenter, Randomized, Double-Blind, 24-Week Study of the Clinical and Antiviral Effect of S-217622 Compared With Placebo in Non-Hospitalized Participants With COVID-19
Aug 12, 2026TrialA Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety, Tolerability, and Efficacy of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus Who Are at High Risk of Progression to Severe Disease
4 more events
Aug 7, 2026TrialA Phase 2, Open-label, Multicenter, Extension Study to Investigate the Long-term Safety and Efficacy of S-606001 in Patients With Late-onset Pompe Disease
Jul 31, 2026TrialEdaravone-Sodium Ozagrel (Thromboxane A2 Synthase Inhibitor) Comparative Post-Marketing Study on Acute Ischemic Stroke
Jul 31, 2026TrialA Phase 2b, Multinational, Randomized, Double-blind Study to Investigate the Efficacy and Safety of Redasemtide (S-005151) Compared With Placebo in Adult Participants With Acute Ischemic Stroke
Jul 29, 2026TrialA Phase 1/2, Multicentre, Open-label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Naldemedine in Paediatric Patients Who Are Receiving or Who Are About to Receive Treatment With Opioids
Details
Company Info
Company Overview
$20.0B
Mkt Cap
$2.8B
Revenue
—
Cash
CEOIsao Teshirogi
Founded1878
Employees12,000
HQOsaka, Japan, Japan
ExchangeOTC:SGIOF
Websiteshionogi.com
LinkedInCompany Page
Therapeutic Focus
Infectious DiseaseGastroenterologyNephrologyNeurologyCardiovascularOtherRare DiseaseOncology
Pipeline
Drug Pipeline
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Infectious Disease
Regulatory
Regulatory Timeline
19931 event
FDASep 9
Cognex — COGNEX
Application NDA020070 (NDA)
20092 events
FDAApr 9
Ulesfia — ULESFIA
Application NDA022129 (NDA)
FDAApr 9
Ulesfia — ULESFIA
Application NDA022129 (NDA)
20101 event
FDAOct 5
Doribax — DORIBAX
Application NDA022106 (NDA)
20171 event
FDAMay 5
Radicava — RADICAVA
Application NDA209176 (NDA)
20191 event
FDANov 14
Fetroja — FETROJA
Application NDA209445 (NDA)
20221 event
FDAMay 12
Radicava — RADICAVA ORS
Application NDA215446 (NDA)
20261 event
FDAMay 29
Xocova — XOCOVA
Application NDA220442 (NDA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)